Education
About Us
Working with TipRanks
Follow Us
Immuneering Corp. Class A (IMRX)
:IMRX
IMRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.00 - $3.83
Previous CloseN/A
Volume3.55M
Average Volume (3M)157.44K
Market Cap
$49.66M
Enterprise Value$36.33M
Total Cash (Recent Filing)$36.14M
Total Debt (Recent Filing)$4.16M
Price to Earnings (P/E)―
Beta2.41
Next Earnings
May 13, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.03
Shares Outstanding35,985,703
10 Day Avg. Volume152,322
30 Day Avg. Volume157,437
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2910.98
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$12.00Price Target Upside751.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Immuneering News
PremiumCompany Announcements
Immuneering Corp. Reports Promising Cancer Trial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsInitial Phase 2a efficacy data from IMM-1-104 in combination with chemotherapy shows a promising overall response rate of 40% and a disease control rate of 80%.
Financial ProjectionsThe stock is expected to rise based on positive data supporting the development of IMM-1-104 plus chemo combo in 1L PDAC.
PartnershipsImmuneering announced a clinical supply agreement with Regeneron Pharmaceutical which will enable IMM-1-104 to be tested in combination with Libtayo in a Ph 2A study.
Bears Say
EarningsIMRX reported an EPS of -$0.58 for 4Q24, lower than consensus of -$0.43 with slightly higher R&D ($0.9M var).
Financial PerformanceImmuneering raised net proceeds of $13.7M through its ATM following its update.
Research And DevelopmentThe appointment of Dr. Igor Matushansky as the CMO brings extensive oncology drug development expertise to the company.
---
Ownership Overview
16.39% Insiders
5.19% Mutual Funds
1.07% Other Institutional Investors
74.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMRX FAQ
What was Immuneering Corp. Class A’s price range in the past 12 months?
Immuneering Corp. Class A lowest stock price was $1.00 and its highest was $3.83 in the past 12 months.
What is Immuneering Corp. Class A’s market cap?
Immuneering Corp. Class A’s market cap is $49.66M.
When is Immuneering Corp. Class A’s upcoming earnings report date?
Immuneering Corp. Class A’s upcoming earnings report date is May 13, 2025 which is in 18 days.
How were Immuneering Corp. Class A’s earnings last quarter?
Immuneering Corp. Class A released its earnings results on Mar 20, 2025. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.416 by -$0.164.
Is Immuneering Corp. Class A overvalued?
According to Wall Street analysts Immuneering Corp. Class A’s price is currently Undervalued.
Does Immuneering Corp. Class A pay dividends?
Immuneering Corp. Class A does not currently pay dividends.
What is Immuneering Corp. Class A’s EPS estimate?
Immuneering Corp. Class A’s EPS estimate is -0.53.
How many shares outstanding does Immuneering Corp. Class A have?
Immuneering Corp. Class A has 35,985,703 shares outstanding.
What happened to Immuneering Corp. Class A’s price movement after its last earnings report?
Immuneering Corp. Class A reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.416. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Immuneering Corp. Class A?
Among the largest hedge funds holding Immuneering Corp. Class A’s share is Perceptive Advisors LLC. It holds Immuneering Corp. Class A’s shares valued at 0.
---
Immuneering Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (751.06% Upside)
$12.00 (751.06% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.49%
12-Months-Change
Fundamentals
Return on Equity
-92.51%
Trailing 12-Months
Asset Growth
-48.61%
Trailing 12-Months
Company Description
Immuneering Corp. Class A
Immuneering Corporation (IMRX) is a biopharmaceutical company focused on developing innovative drug candidates for the treatment of cancer and other diseases. The company's approach is centered around its proprietary platform that harnesses computational biology to unravel complex biological data and identify potential therapeutic targets. Immuneering aims to advance precision medicine by creating effective treatments that can precisely target specific disease pathways, offering new hope for patients with unmet medical needs.
---
IMRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(751.06% Upside)
Technical Analysis
Bluebird Bio
―
Adicet Bio
―
Precision BioSciences
―
MAIA Biotechnology, Inc.
―
Acrivon Therapeutics, Inc.
―
Best Analysts Covering IMRX
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-23.46%
reiterated a buy rating 8 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -23.46% per trade.
---